Andreas Halvorsen co-founded Viking Global together his Tiger Management colleagues David Ott and Brian Olson back in 1999. Viking follows a bottom......
(read more)September 22 - Hedge Fund Analysis, Hedge Funds, Stock Analysis - Comments
Results for a potentially game-changing proof of concept study were just published concerning malaria by Novartis AG (NYSE:NVS) in the New England Journal......
(read more)September 22 - News, Stock Analysis - Comments
Marc Lasry is the co-founder of Avenue Capital, which was launched with $7 million in funding from friends and family in 1995, and currently holds the......
(read more)September 21 - Hedge Fund Analysis, Hedge Funds, Stock Analysis - Comments
Janssen Pharmaceuticals, a subsidiary of the giant manufacturing company, Johnson & Johnson (NYSE:JNJ) has expanded the current partnership with......
(read more)September 21 - News, Stock Analysis - Comments
Numerous complaints by medical charity Medecins Sans Frontieres over the cost of pneumococcal vaccine given to refugees by GlaxoSmithKline PLC (ADR) (......
(read more)September 20 - News, Stock Analysis - Comments
Romosozumab (AKA romo) from Amgen Inc (NASDAQ:AMGN) and Belgium-based UCB, which is in its Phase III FRAME study is yet to achieve any regulatory approval......
(read more)September 20 - News, Stock Analysis - Comments
Something is happening with Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP). Since February, the stock has risen 600%, 158% since August alone. Not......
(read more)September 19 - News, Stock Analysis - Comments
Investors who play the developing biotech niche are always on the lookout for shortcuts to approval. A shortcut can come in two ways. First, they can......
(read more)September 19 - News, Stock Analysis - Comments
On September 14, the Food and Drug Administration released two briefing documents for the joint meeting of two committees. These are the Psychopharmacologic......
(read more)September 16 - News, Stock Analysis - Comments
When things go well in biotech, it can be a great ride. When things repeatedly go well, however, it can be easy to forget how quickly, and how frequently......
(read more)September 16 - News, Stock Analysis - Comments
It has been a roller-coaster ride for equity investors so far this year. The year began on a disastrous note as risk assets saw a huge sell-off amid concerns......
(read more)September 14 - News, Stock Analysis - Comments
Equities have rebounded in trading today following the sell-off on Tuesday. Investors though remain anxious due to uncertainty over when the Federal Reserve......
(read more)September 14 - News, Stock Analysis - Comments
Mast Therapeutics Inc (NYSEMKT:MSTX) lost nearly 25% of its market capitalization on Tuesday, as the company failed to serve up an expected presentation......
(read more)September 14 - News, Stock Analysis - Comments
Barrick Gold Corporation (USA) (NYSE:ABX), billed as the world’s leading gold producer, is up to something big: digitizing company-wide operations.......
(read more)September 14 - News, Stock Analysis - Comments
TESARO Inc (NASDAQ:TSRO) just announced that the FDA has granted Fast Track designation to its lead ovarian, fallopian tube, or primary peritoneal cancer......
(read more)September 14 - News, Stock Analysis - Comments
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) gained considerably at the end of last week on the back of a data release from its ongoing type 1 diabetes......
(read more)September 13 - News, Stock Analysis - Comments
As we noted last week, the close of the third quarter and the start of the final quarter of the year is when volume really starts to pick up in wider......
(read more)September 13 - News, Stock Analysis - Comments
Introduction On June 28, 2016, the Endocrinologic and Metabolic Drugs Advisory Committee of the Food and Drug Administration (FDA) met to discuss and......
(read more)September 9 - News, Stock Analysis - Comments
In 2014, Dr. Thomas Insel, the former director of the National Institute of Mental Health (NIMH), wrote in a blog post that intravenous ketamine “might......
(read more)September 8 - News, Stock Analysis - Comments
Repros Therapeutics Inc (NASDAQ:RPRX) just put out data from its phase II in moderate to severe endometriosis, and the company has gained close to 17%......
(read more)September 8 - News, Stock Analysis - Comments
Summer is officially over, and the warm weather volume lull is has come to an end. It’s time for money movers to get back in front of their machines......
(read more)September 7 - News, Stock Analysis - Comments
Dave & Buster’s Entertainment, Inc. (NASDAQ:PLAY) shares are off this morning after posting disappointing same-store sales in yesterday’s earnings......
(read more)September 7 - News, Stock Analysis - Comments
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) just announced that the FDA has delayed its PDUFA for the companies lead Batten Disease candidate, meaning......
(read more)September 7 - News, Stock Analysis - Comments
Towards the end of August, we published this piece detailing two major potential upside catalysts to keep an eye on early September. One of the companies......
(read more)September 6 - News, Stock Analysis - Comments
Update: Several hours after the initial publication of this report on September 2, Novo Nordisk announced that the FDA has extended the regulatory......
(read more)September 6 - News, Stock Analysis - Comments
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) just reported that the FDA has granted Orphan Drug Designation to its lead development candidate, and the company......
(read more)September 6 - News, Stock Analysis - Comments
Despite the labor day halt in the US, the end of the week last week brought with it plenty of volatility, and as we move into the start of a fresh week......
(read more)September 6 - News, Stock Analysis - Comments
Array Biopharma Inc (NASDAQ:ARRY) just had its latest NDA accepted by the FDA, and the agency has put forward a PDUFA date for the candidate of June 30......
(read more)September 2 - News, Stock Analysis - Comments
Kindred Healthcare, Inc. (NYSE:KND) is a healthcare services company that operates hospitals, home health, hospice, nursing centers, and non-medical......
(read more)September 2 - News, Stock Analysis - Comments
Hertz Global Holdings, Inc (NYSE:HTZ) is one of the largest general use vehicle rental businesses in the world. In this article, we will take a closer......
(read more)September 2 - News, Stock Analysis - Comments
Eli Lilly and Co (NYSE:LLY) is one of the largest drug companies in the world. In this article, we’ll take a closer look at why many hedge funds......
(read more)September 2 - Hedge Funds, News, Stock Analysis - Comments
United Technologies Corporation (NYSE:UTX) is one of the largest, most diversified industrial conglomerates in the world. In this article, we’ll......
(read more)September 2 - Hedge Funds, News, Stock Analysis - Comments
Sinclair Broadcast Group Inc (NASDAQ:SBGI) is the largest and most diversified TV broadcasting company in the United States, with around 173 stations......
(read more)September 2 - Hedge Funds, News, Stock Analysis - Comments
News just broke that Toronto based biotech Cynapsus Therapeutics Inc (NASDAQ:CYNA) is set to be bought out by Sunovion Pharmaceuticals, and shares of......
(read more)September 1 - News, Stock Analysis - Comments
Gulfport Energy Corporation (NASDAQ:GPOR) is a leading natural gas-focused E&P with 243,000 net acres in the Utica shale and 11,002 net acres in......
(read more)September 1 - Commodities, Hedge Funds, News, Stock Analysis - Comments
Graphic Packaging Holding Company (NYSE:GPK) is a leading global paperboard packaging company. In this article, we’ll take a closer look at the......
(read more)September 1 - Hedge Funds, News, Stock Analysis - Comments
Portola Pharmaceuticals Inc (NASDAQ:PTLA) is a $1.17 billion biopharmaceutical company and potential takeover candidate that develops and commercializes......
(read more)August 31 - News, Stock Analysis - Comments
Karyopharm Therapeutics Inc (NASDAQ:KPTI) is set to report an overview of the topline data from its lead multiple myeloma trial on September 6 and markets......
(read more)August 31 - News, Stock Analysis - Comments
Acorda Therapeutics Inc (NASDAQ:ACOR) is a $1.11 billion biotechnology company that develops and commercializes novel therapies for neurological disorders......
(read more)August 31 - News, Stock Analysis - Comments
Five Prime Therapeutics Inc (NASDAQ:FPRX) is a $1.25 billion biotech company that focuses on the discovery and development of protein therapeutics that......
(read more)August 31 - News, Stock Analysis - Comments
Clovis Oncology Inc (NASDAQ:CLVS) is a biopharmaceutical company focused on developing and commercializing anti-cancer agents. In this article, we examine......
(read more)August 31 - News, Stock Analysis - Comments
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) just put out data from its lead pivotal, and the company is up close to 50% on the numbers. Needless to say,......
(read more)August 30 - News, Stock Analysis - Comments
It’s rare for a developing biotech to trade in a pattern that resembles a more established pharma company with much higher liquidity. When it happens......
(read more)August 30 - News, Stock Analysis - Comments
A little known Californian biotech working on a liver disease drug just hit international headlines on suggestions that it might be an effective treatment......
(read more)August 30 - News, Stock Analysis - Comments
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) is an $817 million platform company with four products: Feraheme, a treatment for iron deficiency anemia (IDA......
(read more)August 30 - Hedge Funds, News, Stock Analysis - Comments
Gaming and Leisure Properties Inc (NASDAQ:GLPI) is a $6.9 billion REIT that leases out real estate property to gaming operators in triple net lease arrangements......
(read more)August 30 - Dividend Stocks, Hedge Funds, News, Stock Analysis - Comments
Novartis AG (ADR) (NYSE:NVS) just put out data from its multiple sclerosis (MS) trial, and it looks as if the company is winning the race to bring a drug......
(read more)August 29 - News, Stock Analysis - Comments
Introduction Back on May 12, 2015, the Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee released a briefing......
(read more)August 29 - News, Stock Analysis - Comments
Neuroderm Ltd (NASDAQ:NDRM) just announced the kicking off of a pivotal trial in its lead Parkinson’s disease (PD) candidate, and the company has taken......
(read more)August 29 - News, Stock Analysis - Comments
Novartis AG (NYSE:NVS) has announced that the Phase III EXPAND study, which is evaluating the efficacy and safety of oral, once daily, BAF312 in secondary......
(read more)August 26 - News, Stock Analysis - Comments
